IRIS
VITIELLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.391
EU - Europa 751
AS - Asia 699
SA - Sud America 105
Continente sconosciuto - Info sul continente non disponibili 69
AF - Africa 12
OC - Oceania 1
Totale 3.028
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.340
RU - Federazione Russa 420
SG - Singapore 275
IT - Italia 187
CN - Cina 171
BR - Brasile 84
BD - Bangladesh 71
HK - Hong Kong 52
VN - Vietnam 51
CA - Canada 30
DE - Germania 30
GB - Regno Unito 30
FR - Francia 28
IN - India 22
JP - Giappone 15
NL - Olanda 12
AR - Argentina 9
MX - Messico 9
PL - Polonia 9
ES - Italia 6
FI - Finlandia 6
SE - Svezia 6
SA - Arabia Saudita 5
ID - Indonesia 4
LT - Lituania 4
MY - Malesia 4
TR - Turchia 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
IQ - Iraq 3
IR - Iran 3
JM - Giamaica 3
MA - Marocco 3
NP - Nepal 3
PK - Pakistan 3
VE - Venezuela 3
BE - Belgio 2
BO - Bolivia 2
CO - Colombia 2
CR - Costa Rica 2
EC - Ecuador 2
EG - Egitto 2
NI - Nicaragua 2
SV - El Salvador 2
TW - Taiwan 2
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CG - Congo 1
GT - Guatemala 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MV - Maldive 1
PE - Perù 1
PH - Filippine 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 2.959
Salva come PNG Salva come JPEG
Città #
Dallas 734
Singapore 186
Ashburn 89
Moscow 75
San Jose 61
Hong Kong 50
Beijing 47
New York 40
Los Angeles 33
Milan 31
Santa Clara 26
Council Bluffs 25
Phoenix 21
Ho Chi Minh City 19
Munich 17
Orem 16
Rome 15
Lauterbourg 14
Hanoi 13
São Paulo 12
Tokyo 12
Toronto 11
Montreal 10
Boardman 9
Chicago 9
Naples 9
Brooklyn 8
Hefei 8
London 8
Poplar 8
Boston 7
Manchester 7
Warsaw 7
Atlanta 6
Bacoli 6
Denver 6
Frankfurt am Main 6
Guangzhou 6
Secaucus 6
Shanghai 6
Stockholm 6
Bari 5
Cesano Boscone 5
Chennai 5
North Bergen 5
West Palm Beach 5
Dhaka 4
Mexico City 4
Monza 4
Mumbai 4
Newark 4
Omaha 4
Riyadh 4
Tianjin 4
Venice 4
Amsterdam 3
Belo Horizonte 3
Bologna 3
Buffalo 3
Cleveland 3
Columbus 3
Da Nang 3
Eatonton 3
Helsinki 3
Houston 3
Johannesburg 3
Miano 3
Milwaukee 3
Nanning 3
Porto Alegre 3
Querétaro 3
San Francisco 3
Shenzhen 3
Turin 3
Washington 3
Agadir 2
Ankara 2
Biên Hòa 2
Brescia 2
Brussels 2
Cagliari 2
Cape Coral 2
Charlotte 2
Chengdu 2
Colombo 2
Duque de Caxias 2
Forcalquier 2
Formosa 2
Fortaleza 2
Genoa 2
Guarulhos 2
Helena 2
Ipoh 2
Islington 2
Jinhua 2
Kathmandu 2
Kolkata 2
Lancaster 2
Lappeenranta 2
Managua 2
Totale 1.856
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 445
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 428
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 162
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 156
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 141
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 141
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 136
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 126
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 125
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 120
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 117
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 115
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 106
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 105
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 104
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 100
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 99
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 88
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 85
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 82
Comprehensive genetic analysis in biliary tract cancer: a prospective single-center experience 15
Unleashing precision: A review of targeted approaches in pleural mesothelioma 15
Immunotherapy in small bowel adenocarcinoma: a potential role? 10
null 7
Totale 3.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.217
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.217
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202412 0 0 0 0 0 0 0 0 0 1 6 5
2024/2025117 6 0 0 3 8 10 11 16 5 5 10 43
2025/20262.515 114 390 489 231 176 79 105 159 406 92 149 125
2026/2027384 89 92 98 105 0 0 0 0 0 0 0 0
Totale 3.028